Cancer antigen 125 (CA125) is the most used serum marker and the most trusted method for early detection of ovarian cancer. CD BioGlyco offers multiple highly sensitive and specific ovarian cancer assays based on CA125. We look forward to being your scientific assistant in the field of glycoproteomics.

CA125

Endometrial cancer, cervical cancer and ovarian cancer are three of the most common malignancies of the female reproductive tract. Of these three cancers, ovarian cancer, although rare, is the most lethal, primarily because approximately three-quarters of ovarian cancer cases are diagnosed at an advanced stage and the disease has spread to organs outside the ovaries. The poor prognosis for this cancer is directly attributable to the lack of sensitive and reliable screening assays and our limited understanding of its chemoresistance and recurrence mechanisms. Therefore, the establishment of appropriate early screening tests for ovarian cancer has long been sought.

One of the most commonly used protein tests for the initial detection of various types of cancer, including ovarian cancer, is based on serum levels of CA125 cancer antigen, which is a very important tumor glyco-biomarker with a normal level at 35 U/mL. This level is elevated in advanced ovarian cancer and in malignant tumors such as colon, breast, pericardium, pancreas and other epithelial cell diseases. Today, screening for ovarian cancer using CA125 is performed in combination with physical examination and its early detection is critical to achieving an effective ovarian cancer diagnosis so that treatment programs can be initiated at the onset of the disease.

Fig.1 Schematic of the sandwich immunoassay for CA125. (mAb-capture antibody; Ab-AP- alkaline phosphatase labeled detection antibody; antigen-CA125). (Al-Ogaidi, 2013)

Our Strategies

CD BioGlyco has developed sensitive, reliable and rapid methods for detecting low levels of CA125 that are indicative of early ovarian cancer. The strategies we provide include but are not limited to:

• We have developed an enzyme immunoassay based on a dual signal transduction mechanism for the detection of the glyco-biomarker CA125. The nanoelectrode array (NEA) is used to confirm the optical detection of CA125 in a highly bound 96-well plate. Alkaline phosphatase (AP) enzyme is used to label the detection antibody for optical and electrochemical detection of CA125.
• We have developed a label-free and array-based optical liquid-crystal immunoassay technique for the detection of CA125 antigen, providing an alternative and sensitive method for the detection of biomarker proteins.
• We have developed a dual gold nanostructure-based electrochemical immunosensor for the detection of the biomarker CA125 in serum. This immunosensor is stable and has good correlation coefficients for clinical serum samples tested using the developed immunosensor and enzyme-linked immunosorbent assay (ELISA).

Applications

• Earlier stage screening test for ovarian cancer
• Patient diagnosis, prognosis and clinical management
• Screening and monitoring response to therapy
• Detecting earlier recurrence during follow-up

Advantages of Us

• Fast and noninvasive detection
• Screening strategies with high sensitivity and specificity
• Process modification according to customer requirements

CD BioGlyco is committed to developing new cancer glyco-biomarker assays including CA125 assay to reduce the cost of detection systems and simplify cancer screening procedures. If you have a need for glyco-biomarker detection services, please contact us for further information.

Reference

1. Al-Ogaidi, I.; et al. Dual detection of cancer biomarker CA125 using absorbance and electrochemical methods. Analyst. 2013, 138(19):5647-5653.